Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bernard-Marty, C.
Right arrow Articles by Di Leo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernard-Marty, C.
Right arrow Articles by Di Leo, A.
Related Collections
Right arrow 2003 - Editors Choice
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:693-698, 2003
© 2003 European Society for Medical Oncology

Original Paper

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients

C. Bernard-Marty1, M. Mano1, M. Paesmans1, C. Accettura1, R. Munoz-Bermeo1, T. Richard1, K. Kleiber1, F. Cardoso1, J. P. Lobelle2, D. Larsimont1, M. J. Piccart1 and A. Di Leo1,+

1 Jules Bordet Institute, Brussels; 2 Pharmacia, Diegem, Belgium

Received 8 July 2002; revised 25 November 2002; accepted 19 December 2002

Background:

Alkylating agents and topoisomerase-II inhibitors have been associated with the occurrence of secondary leukemias and myelodysplastic syndromes in breast cancer patients treated with adjuvant chemotherapy. Conversely, data on the occurrence of second solid malignancies in this setting are scarce.

Patients and methods:

This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin–cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer.

Results:

At a median follow-up of 73 months, the following 8-year actuarial rates of second solid primaries were observed: CMF 5.5% [95% confidence interval (CI) 1.5% to 9.5%], EC 4.1% (95% CI 0.1% to 8.1%), and HEC 7.2% (95% CI 3.2% to 11.2%) (P = 0.79 by log rank test). Three secondary acute myeloid leukemias (AML) were reported, all in the HEC arm (incidence = 1.2%, 95% CI 0.0% to 2.5%), which by a three arm comparison allows us to conclude that HEC is statistically different (borderline significance) from CMF and EC (P = 0.05).

Conclusions:

HEC, as delivered in this trial, cannot be recommended in clinical practice because of the lack of superiority over classic CMF and because of the increased risk of AML observed in this arm. Prolongation of conventional anthracycline-based treatment beyond the current standard of four to six cycles is not recommended in clinical practice.

Key words: anthracyclines, breast cancer, second tumors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Beadle, P. Baade, and L. Fritschi
Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers
Ann. Onc., January 1, 2009; 20(1): 103 - 109.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Lichtman
Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia?
Oncologist, June 1, 2008; 13(6): 645 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
N. Kopjar, I. Milas, V. Garaj-Vrhovac, and M. Gamulin
Cytogenetic outcomes of adjuvant chemotherapy in non-target cells of breast cancer patients
Human and Experimental Toxicology, May 1, 2007; 26(5): 391 - 399.
[Abstract] [PDF]

Home page
 JCOHome page
M.-C. Le Deley, F. Suzan, B. Cutuli, S. Delaloge, A. Shamsaldin, C. Linassier, S. Clisant, F. de Vathaire, P. Fenaux, and C. Hill
Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer
J. Clin. Oncol., January 20, 2007; 25(3): 292 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Campone, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al.
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
Ann. Onc., August 1, 2005; 16(8): 1343 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Praga, J. Bergh, J. Bliss, J. Bonneterre, B. Cesana, R. C. Coombes, P. Fargeot, A. Folin, P. Fumoleau, R. Giuliani, et al.
Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide
J. Clin. Oncol., June 20, 2005; 23(18): 4179 - 4191.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Arriagada and J. Gutierrez
Anthracyclines: is more, better and/or more dangerous?
Ann. Onc., May 1, 2003; 14(5): 663 - 665.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.